SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement

The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.

SCG Cell Therapy (SCG) and the Agency for Science, Technology and Research (A*STAR) have launched joint laboratories to produce novel cell therapies that meet good manufacturing practice (GMP) standards.

With a combined funding of almost $30m, the partnership will focus on induced pluripotent stem cell (iPSC) technology and develop scalable GMP-grade iPSC manufacturing processes and therapeutic candidates.

"The discovery of iPSCs has revolutionised regenerative medicine, offering the potential for standardised, off-the-shelf cell therapies.” Koh Boon Tong, Executive Director, A*STAR's BTI, said.

ALSO READ: NUH to establish health centre for early cancer detection in 2025

The joint laboratories are established at SCG’s GMP facility and A*STAR’s research facility.

Meanwhile, the two organisations also plan to establish a talent development programme to conduct training following current GMP and regulatory requirements.